Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CNTB vs SRZN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SRZN Captures Overall Composite Edge (33.2 SELL vs 41.0 SELL), While CNTB Leads 4–1 on Growth & Valuation Pillars
SRZN Overall Winner
6-Pillar Tally: CNTB 4 – 1 SRZN (1 Tie)
Matrix Metrics: CNTB 4 – 5 SRZN
As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (33.2/100 SELL vs. 41.0/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. CNTB trades at $0.59 (0.8x Forward P/E, -2384.5% operating margin) versus SRZN at $29.93 (N/M Forward P/E, -485.4% operating margin).
- Composite vs. Pillar Nuance: While CNTB currently prints a higher short-term Unified Composite Score (41.0/100 SELL vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -2384.5% operating margin) and revenue trajectory (+408.6% vs. +5666.7% YoY).
- Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both CNTB (41.0/100 SELL) and SRZN (33.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
- Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CNTB vs SRZN
CNTB
Connect Biopharma Holdings Limited Ordinary Shares
$0.59
-7.94% 1D
Market Cap
$42.6M
TTM Revenue
$3.0M
Forward P/E
0.8x
Beta / 30D Vol
0.92β · 68% Vol
Unified Composite Score
41.0
SELL
Tech 25.0
Fund 48.0
Flow 66.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
SRZN
Head-to-Head Winner
Surrozen, Inc. Common
$29.93
-7.38% 1D
Market Cap
$602.5M
TTM Revenue
$11M
Forward P/E
N/M
Beta / 30D Vol
1.28β · 66% Vol
Unified Composite Score
33.2
SELL
Tech 50.0
Fund 34.0
Flow 65.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (CNTB 4 – 1 SRZN)
1. Valuation Multiples
CNTB
Forward P/E
0.8x
N/M
Trailing P/E
0.8x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
5.5x
48.3x
2. Growth & Scale
CNTB
Revenue Growth (YoY)
+5666.7%
+408.6%
Earnings Growth (YoY)
+0.0%
-37.0%
TTM Revenue (USD)
$3.0M
$11M
Market Cap
$42.6M
$602.5M
3. Profitability & Quality
SRZN
Gross Margin
100.0%
N/A
Operating Margin
-2384.5%
-485.4%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-140.5%
-62.8%
4. Balance Sheet & Cash Flow
CNTB
Cash Generation (TTM)
-$61M
-$31M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$26M Net Cash
$95M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CNTB
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
397.3% (100th %ile)
72.0% (5th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CNTB (4) vs SRZN (5)| Institutional Metric | CNTB | SRZN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $42.6M | $602.5M | SRZN | |
| Trailing P/E Ratio | 0.8x | N/M | CNTB | |
| Forward P/E Ratio | 0.8x | N/M | CNTB | |
| Revenue Growth (YoY) | +5666.7% | +408.6% | CNTB | |
| Operating Margin (TTM) | -2384.5% | -485.4% | SRZN | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -140.5% | -62.8% | SRZN | |
| 52-Week Range Position | 1% ($1–$4) | 69% ($12–$38) | SRZN | |
| Beta / 30D Volatility | 0.92β · 68% Vol | 1.28β · 66% Vol | SRZN | |
| Unified Institutional Score | 41.0 / 100 (SELL) | 33.2 / 100 (SELL) | CNTB | |
| Trailing 12M Revenue (USD) | $3.0M | $11M | Scale | |
| Gross Profit Margin (TTM) | 100.0% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 5.5x EV/Rev | N/M PEG · 48.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$61M ($26M Net Cash) | -$31M ($95M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SRZN +59.79 pp
3M Horizon
SRZN +100.62 pp
6M Horizon
SRZN +90.04 pp
1Y Horizon
SRZN +202.7 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CNTB Revenue | SRZN Revenue | CNTB Op. Margin | SRZN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2022 | N/A | $10M | N/A | -354.7% | SRZN |
| FY2024 | $30M | $10M | -86.2% | -239.7% | CNTB |
| FY2025 | $0M | $0M | -90740.6% | -1210.6% | SRZN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CNTB
UNCLASSIFIED
Current IV
397.3%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CNTB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
SRZN
CONSOLIDATION
Current IV
72.0%
IV Percentile
5th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CNTB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
SRZN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CNTB vs SRZN Key Questions & Quantitative Answers
As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (33.2/100 SELL vs. 41.0/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. CNTB trades at $0.59 (0.8x Forward P/E, -2384.5% operating margin) versus SRZN at $29.93 (N/M Forward P/E, -485.4% operating margin). Composite vs. Pillar Nuance: While CNTB currently prints a higher short-term Unified Composite Score (41.0/100 SELL vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -2384.5% operating margin) and revenue trajectory (+408.6% vs. +5666.7% YoY). Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both CNTB (41.0/100 SELL) and SRZN (33.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CNTB leads the Growth & Scale pillar: CNTB posts +5666.7% YoY revenue growth and +0.0% YoY earnings growth on $3.0M TTM revenue (100.0% gross margin, -2384.5% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 3-period historical trajectory (FY2022 to FY2025), CNTB cumulative revenue shifted N/A while SRZN shifted +0.0%. In operating R&D and SG&A reinvestment, CNTB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.
CNTB screens cheaper on headline valuation multiples. CNTB trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (unreported FCF margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNTB (-140.5% ROE) versus SRZN (-62.8% ROE) capital efficiency.
In options market volatility and institutional positioning, CNTB carries 397.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 68% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 66% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
SRZN vs CNTB · Reverse Pair
CNTB vs UNCY
· Sector Peer
SRZN vs FTH
· Sector Peer
SRZN vs JSPR
· Sector Peer
SRZN vs TIL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma